Published on:

Bydureon

In the middle of a not so good stock market Friday after the jobs report, Amylin Pharmaceuticals went up 5% after a new study of its diabetes drug Bydureon took a step forward towards reaching the market.

Rezulin, Actos, Avandia… it seems there are a few diabetes drugs that have come on to the market with controversy and, yes, lawsuits. Is Bydureon different? I guess we are going to find out.

Our firm is now reviewing potential Bydureon lawsuits. Call us today for a free consultation. (I’m just kidding, by the way. Hopefully, Bydureon is a safe and efficacious drug that just helps people like the vast majority of drugs and medical devices.)